Meer inligting ― Afrikaans

Urticarial vasculitis is 'n seldsame toestand wat gekenmerk word deur langdurige of herhalende episodes van korwe. Alhoewel sy velsimptome soos chroniese korwe kan lyk, is hulle uniek omdat die korwe vir ten minste 24 uur bly sit en donker kolle kan veroorsaak nadat hulle vervaag. Alhoewel dit dikwels van onbekende oorsaak is, kan dit soms veroorsaak word deur sekere medikasie, infeksies, outo-immuun siektes, bloedafwykings of kankers. Sommige studies het dit selfs aan COVID-19 en H1N1-griep gekoppel. Dit kan ook ander dele van die liggaam beïnvloed, soos spiere, niere, longe, maag en oë. Alhoewel 'n sekere tipe weefselondersoek die diagnose kan bevestig, is dit nie altyd nodig nie. Behandeling begin tipies met antibiotika, dapson, kolgisien of hidroksichlorokien vir ligter gevalle. Vir meer ernstige gevalle kan middels wat die immuunstelsel onderdruk, soos metotreksaat of kortikosteroïede, nodig wees. Onlangs het biologiese terapieë (rituximab, omalizumab, interleukin-1 inhibitors) belofte getoon vir moeilike gevalle.
Urticarial vasculitis is a rare clinicopathologic entity that is characterized by chronic or recurrent episodes of urticarial lesions. Skin findings of this disease can be difficult to distinguish visually from those of chronic idiopathic urticaria but are unique in that individual lesions persist for ≥24 hours and can leave behind dusky hyperpigmentation. This disease is most often idiopathic but has been linked to certain drugs, infections, autoimmune connective disease, myelodysplastic disorders, and malignancies. More recently, some authors have reported associations between urticarial vasculitis and COVID-19, as well as influenza A/H1N1 infection. Urticarial vasculitis can extend systemically as well, most often affecting the musculoskeletal, renal, pulmonary, gastrointestinal, and ocular systems. Features of leukocytoclastic vasculitis seen on histopathologic examination are diagnostic of this disease, but not always seen. In practice, antibiotics, dapsone, colchicine, and hydroxychloroquine are popular first-line therapies, especially for mild cutaneous disease. In more severe cases, immunosuppressives, including methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine, as well as corticosteroids, may be necessary for control. More recently, select biologic therapies, including rituximab, omalizumab, and interleukin-1 inhibitors have shown promise for the treatment of recalcitrant or refractory cases.

'n 35-jarige man het ingekom met 'n 15-dae geskiedenis van helderrooi, pynlike uitslag op beide dye en bene, saam met gewrigspyn. Hy het ’n week lank ’n urienweginfeksie gehad voordat die uitslag verskyn het. Sy vel het verskeie sagte, ringvormige, gedeeltelik blansjeerbare, rooi plate aan beide kante van sy dye en bene getoon. Hy is vir 'n week orale prednisoloon (40mg/dag) saam met 'n nie-dromerige antihistamien (fexofenadine) gegee. Binne 'n week het al die uitslag heeltemal verdwyn. Daar was nie meer uitslag gedurende die volgende 6 maande van gereelde ondersoeke nie.
A 35-year-old man came in with a 15-day history of bright red, painful rashes on both thighs and legs, along with joint pain. He had a urinary tract infection for a week before the rash appeared. His skin showed several tender, ring-shaped, partially blanchable, red plaques on both sides of his thighs and legs. He was given oral prednisolone (40mg/day) for a week along with a non-drowsy antihistamine (fexofenadine). Within a week, all the rashes disappeared completely. There were no more rashes during the next 6 months of regular check-ups.